Prevention of infarct expansion

Patent metadata

Field	Value
Publication number	US-9238046-B2
Application number	US-67914708-A
Country	US
Kind code	B2
Filing date	Sep 19, 2008
Priority date	Sep 21, 2007
Publication date	Jan 19, 2016
Grant date	Jan 19, 2016

Abstract

Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof.

First claim

What is claimed:

1. A method for reducing cardiac remodeling comprising:
placing directly into a cardiac infarct itself, and optionally into a region of tissue containing the infarct, into tissue adjacent to or partially or completely surrounding the infarct, or both, a composition comprising a biologically compatible, acellular material comprising particles having characteristic dimensions of 25 μm to about 50 μm.

2. The method according to claim 1 comprising placing said composition in said infarct less than about one hour following myocardial infarction.

3. The method according to claim 1 wherein said particles comprise microspheres.

4. The method according to claim 1 wherein said material comprises at least one polymer.

5. The method according to claim 1 wherein said material comprises one or more forms of calcium phosphate.

6. The method according to claim 1 wherein said material comprises a glass or a glass-ceramic.

7. The method according to claim 1 wherein said composition further comprises at least one protein, peptide, or amino acid.

8. The method according to claim 1 wherein said material provides structures that support the growth of fibrous tissue in or near said cardiac infarct tissue.

9. A method for reducing post-infarct cardiac remodeling comprising:
increasing the volume of a cardiac infarct wall via injection of a volume-increasing material comprising particles having characteristic dimensions of about 25 μm to about 50 μm directly into said cardiac infarct itself, and optionally into a region of tissue containing the infarct, into tissue adjacent to or partially or completely surrounding the infarct, or both, and,
maintaining substantially all of said material within said cardiac infarct for an extended period of time following said injection.

10. The method according to claim 9 further comprising providing structures that support the growth of fibrous tissue in or near said cardiac infarct.

11. The method according to claim 9 comprising maintaining substantially all of said material within said cardiac infarct for at least about six months following said injection.

12. The method according to claim 9 comprising maintaining substantially all of said material within said cardiac infarct for at least about one year following said injection.

13. The method according to claim 1 wherein said composition further comprises at least one growth factor, enzyme, antibody, or hormone.

Assignees

• Gorman Robert C
• Gorman Iii Joseph H
• Ryan Liam P
• Univ Pennsylvania

Inventors

• Gorman Robert C
• Gorman Iii Joseph H
• Ryan Liam P

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K33/42 Primary

  Phosphorus; Compounds thereof · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61L27/50

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L2430/20

  for reconstruction of the heart, e.g. heart valves · CPC title